Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Protagonist Therapeutics (PTGX) over the last 5 years, with Q3 2025 value amounting to $63.8 million.

  • Protagonist Therapeutics' Shares Outstanding (Diluted Average) fell 129.95% to $63.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.8 million, marking a year-over-year decrease of 129.95%. This contributed to the annual value of $65.1 million for FY2024, which is 1464.7% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $63.8 million for Q3 2025, which was down 129.95% from $63.5 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Shares Outstanding (Diluted Average) peaked at $65.1 million during Q4 2024, and registered a low of $44.2 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $55.6 million, with a median of $56.8 million in 2023.
  • As far as peak fluctuations go, Protagonist Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 2574.79% in 2024, and later crashed by 129.95% in 2025.
  • Protagonist Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $46.3 million in 2021, then rose by 6.01% to $49.1 million in 2022, then rose by 15.59% to $56.8 million in 2023, then rose by 14.65% to $65.1 million in 2024, then decreased by 2.01% to $63.8 million in 2025.
  • Its last three reported values are $63.8 million in Q3 2025, $63.5 million for Q2 2025, and $63.0 million during Q1 2025.